A Phase IC Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Cognitive Outcomes of BI 409306 in Patients with Mild-to-Moderate Schizophrenia
Crossref DOI link: https://doi.org/10.1007/s40120-017-0085-5
Published Online: 2017-11-24
Published Print: 2018-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Brown, David
Daniels, Kristen
Pichereau, Solen
Sand, Michael
Funding for this research was provided by:
Boehringer Ingelheim